

Commission Regulation (EC) No 2701/94 of 7 November 1994 amending Annexes I, II, III and IV to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)

COMMISSION REGULATION (EC) NO 2701/94

of 7 November 1994

amending Annexes I, II, III and IV to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin

(Text with EEA relevance)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin⁽¹⁾, as last amended by Commission Regulation (EC) No 1430/94⁽²⁾, and in particular Articles 6, 7 and 8 thereof,

Whereas, since the adoption of the Regulation, the Annexes have been amended a number of times; whereas, by reason of their number, their complexity and their dispersal among various *Official Journals of the European Communities*, the texts are difficult to use and thus lack the clarity which should be an essential feature of all legislation; whereas, they should therefore be consolidated; whereas on the same occasion the name or chemical description of some compounds should be rectified or made more precise and certain material errors should be corrected;

Whereas the measures provided for in this Regulation are in accordance with the opinion of the Committee for the adaptation to technical progress of directives on the removal of technical barriers to trade in the veterinary medicinal products sector,

HAS ADOPTED THIS REGULATION:

Article 1

Annexes I, II, III and IV to Regulation (EEC) No 2377/90 are hereby amended as set out in the Annex hereto.

Article 2

This Regulation shall enter into force on the 60th day following its publication in the *Official Journal of the European Communities*.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for
the Commission Regulation (EC) No 2701/94. (See end of Document for details)

Done at Brussels, 7 November 1994.

For the Commission

Martin BANGEMANN

Member of the Commission

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

ANNEX

ANNEX I

List of pharmacologically active substances for which maximum residue limits have been fixed

1. Anti-infectious agents

1.1. Chemotherapeutics

1.1.1. Sulfonamides

| Pharmacologically active substance(s) | Maximum residue | Animal species | MRLs | Target tissues | Other provisions |
|---|-----------------|----------------------------|-----------|----------------------------|--|
| All substances belonging to the sulfonamide group | Parent drug | All food producing species | 100 µg/kg | Muscle, liver, kidney, fat | The combined total residues of all substances within the sulfonamide group should not exceed 100 µg/kg |

1.2. Antibiotics

1.2.1. Penicillins

| Pharmacologically active substance(s) | Maximum residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|------------------|----------------------------|----------|----------------------------|------------------|
| 1.2.1.1. Benzylpenicillin | Benzylpenicillin | All food producing species | 50 µg/kg | Muscle, liver, kidney, fat | |
| | | | 4 µg/kg | Milk | |
| 1.2.1.2. Ampicillin | Ampicillin | All food producing species | 50 µg/kg | Muscle, liver, kidney, fat | |
| | | | 4 µg/kg | Milk | |

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

| | | | | | |
|----------|--------------------------------|----------------------------|-----------|----------------------------|--|
| 1.2.1.3. | Amoxicillin Amoxicillin | All food producing species | 50 µg/kg | Muscle, liver, kidney, fat | |
| | | | 4 µg/kg | Milk | |
| 1.2.1.4. | Oxacillin Oxacillin | All food producing species | 300 µg/kg | Muscle, liver, kidney, fat | |
| | | | 30 µg/kg | Milk | |
| 1.2.1.5. | Cloxacillin Cloxacillin | All food producing species | 300 µg/kg | Muscle, liver, kidney, fat | |
| | | | 30 µg/kg | Milk | |
| 1.2.1.6. | Dicloxacillin Dicloxacillin | All food producing species | 300 µg/kg | Muscle, liver, kidney, fat | |
| | | | 30 µg/kg | Milk | |

1.2.2. Cephalosporins

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|---------------|----------------|-----------|----------------|------------------|
| 1.2.2.1. Cefquinome Cefquinome | | Bovine | 200 µg/kg | Kidney | |
| | | | 100 µg/kg | Liver | |
| | | | 50 µg/kg | Muscle | |
| | | | 50 µg/kg | Fat | |

1.2.3. Quinolones

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---|---------------------------------------|--------------------------|----------|-----------------------|------------------|
| 1.2.3.1. Enrofloxacin and ciprofloxacin | Sum of enrofloxacin and ciprofloxacin | Bovine, porcine, poultry | 30 µg/kg | Muscle, liver, kidney | |

1.2.4. Macrolides

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

| Pharmacologically active substance(s) | Maximum residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|-----------------|----------------|-------------|----------------|------------------|
| 1.2.4.1. Tilmicosin | Tilmicosin | Bovine | 1 000 µg/kg | Liver, kidney | |
| | | | 50 µg/kg | Muscle, fat | |

2. Antiparasitic agents

2.1. Agents acting against endoparasites

2.1.1. Avermectins

| Pharmacologically active substance(s) | Maximum residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|-------------------------------------|----------------|-----------|----------------|------------------|
| 2.1.1.1. Ivermectin B1a | 22,23-Dihydro-2H-1-benzofuran-3-one | Bovine | 100 µg/kg | Liver | |
| | | | 40 µg/kg | Fat | |
| | | Porcine | 15 µg/kg | Liver | |
| | | Ovine | 20 µg/kg | Fat | |
| Equidae | | | | | |
| 2.1.1.2. Abamectin B1a | Avermectin B1a | Bovine | 20 µg/kg | Liver | |
| | | | 10 µg/kg | Fat | |
| 2.1.1.3. Doramectin | Doramectin | Bovine | 15 µg/kg | Liver | |
| | | | 25 µg/kg | Fat | |

2.1.2. Salicylanilides

| Pharmacologically active substance(s) | Maximum residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|-----------------|----------------|-------------|----------------|------------------|
| 2.1.2.1. Closantel | Closantel | Bovine | 1 000 µg/kg | Muscle, liver | |
| | | | 3 000 µg/kg | Kidney, fat | |
| | | Ovine | 1 500 µg/kg | Muscle, liver | |
| | | | 5 000 µg/kg | Kidney, fat | |
| | | | 2 000 µg/kg | | |

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

ANNEX II

List of substances not subject to maximum residue limits

1. Inorganic chemicals

| Pharmacologically active substance(s) | Animal species | Other provisions |
|--|----------------------------|-----------------------|
| 1.1. Hydrogen peroxide | Fish | |
| 1.2. Sulphur | Bovine | |
| | Porcine | |
| | Ovine | |
| | Caprine | |
| | Equidae | |
| 1.3. Iodine and iodine inorganic compounds including: — Sodium and potassium — iodide — Sodium and potassium — iodate — Iodophors including polyvinylpyrrolidone — iodine | All food producing species | |
| 1.4. Sodium chlorite | Bovine | For tropical use only |

2. Organic compounds

| Pharmacologically active substance(s) | Animal species | Others provisions |
|---------------------------------------|----------------|-------------------|
| 2.1. Etiproston tromethamine | Bovine | |
| | Porcine | |
| 2.2. Ketanserin tartrate | Equidae | |
| 2.3. Fertirelin acetate | Bovine | |
| 2.4. Human menopausal | Bovine | |

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

| | | | |
|------|--|----------------------------|--|
| | urinary gonadotrophin | | |
| 2.5. | Lactic acid | All food producing species | |
| 2.6. | Melatonin | Ovine | |
| | | Caprine | |
| 2.7. | Iodine organic compounds — Iodoform | All food producing species | |
| 2.8. | Acetyl cysteine | All food producing species | |

ANNEX III

List of pharmacologically active substances used in veterinary medicinal products for which provisional maximum residue limits have been fixed

1. Anti-infectious agents
 - 1.1. Chemotherapeutics
 - 1.1.1. Sulfonamides

| Pharmacologically active substance(s) | Maximum residue | Animal species | MRLs | Target tissues | Other provisions |
|---|-----------------|------------------------|-----------|----------------|---|
| All substances belonging to the sulfonamide group | Parent drug | Bovine, ovine, caprine | 100 µg/kg | Milk | Provisional MRL expires on 1. 1. 1996. The combined total residues of all substances within the sulfonamide group should not exceed 100 µg/kg |

- 1.1.2. Diamino pyrimidine derivates

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|---------------|----------------------------|----------|----------------------------------|---------------------------------------|
| 1.1.2.1. Trimethoprim | Trimethoprim | All food producing species | 50 µg/kg | Muscle, liver, kidney, fat, milk | Provisional MRL expires on 1. 1. 1996 |

1.1.3. Nitrofurans

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|--|----------------------------|---------|----------------------------|---------------------------------------|
| 1.1.3.1. Furazolidone | All residues with intact 5-nitro structure | All food producing species | 5 µg/kg | Muscle, liver, kidney, fat | Provisional MRL expires on 1. 7. 1995 |

1.1.4. Nitroimidazoles

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|---|----------------------------|----------|----------------------------|---------------------------------------|
| 1.1.4.1. Dimetridazole | All residues with intact nitroimidazole structure | All food producing species | 10 µg/kg | Muscle, liver, kidney, fat | Provisional MRL expires on 1. 1. 1995 |

1.2. Antibiotics

1.2.1. Tetracyclines

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|--|---------------|----------------------------|-----------|----------------|--|
| All substances belonging to the tetracycline group | Parent drug | All food producing species | 600 µg/kg | Kidney | Provisional MRLs expire on 1. 1. 1996. The combined total residues of all substances |
| | | | 300 µg/kg | Liver | |
| | | | 200 µg/kg | Eggs | |
| | | | 100 µg/kg | Muscle | |

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

| | | | | | |
|--|--|--|-----------|------|--|
| | | | 100 µg/kg | Milk | within the tetracycline group should not exceed the limits indicated |
|--|--|--|-----------|------|--|

1.2.2. Macrolides

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|---------------|-----------------|-----------|----------------|---|
| 1.2.2.1. Spiramycin | Spiramycin | Bovine, porcine | 300 µg/kg | Liver, | Provisional MRLs expire on 1. 7. 1995. The MRLs for liver, kidney and muscle apply to both the bovine and porcine species |
| | | | 200 µg/kg | Kidney, | |
| | | 50 µg/kg | Muscle | | |
| 1.2.2.2. Tylosin | Tylosin | Bovine | 150 µg/kg | Milk | Provisional MRLs expire on 1. 7. 1995 |
| | | Porcine | | | |
| | | Poultry | | | |
| | | Bovine | 50 µg/kg | Milk | |

1.2.3. Thiamphenicol and related compounds

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|---------------|-----------------|----------|----------------------------|---------------------------------------|
| 1.2.3.1. Thiamphenicol | Thiamphenicol | Bovine, Poultry | 40 µg/kg | Muscle, liver, kidney, fat | Provisional MRL expires on 1. 1. 1996 |

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

2. Antiparasitic agents

2.1. Agents acting against endo-parasites

2.1.1. Benzimidazoles and pro-benzimidazoles

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|--|----------------------------|-------------|---------------------|--|
| 2.1.1.1. Febantel | Combined residues of oxfendazole, oxfendazole sulfone and fenbendazole | All food producing species | 1 000 µg/kg | Liver | Provisional MRLs expire on 1. 7. 1995. The MRLs cover all residues of febantel, fenbendazole and oxfendazole |
| | | | 10 µg/kg | Muscle, kidney, fat | |
| | 10 µg/kg | Milk | | | |
| 2.1.1.2. Fenbendazole | Combined residues of oxfendazole, oxfendazole sulfone and fenbendazole | All food producing species | 1 000 µg/kg | Liver | Provisional MRLs expire on 1. 7. 1995. The MRLs cover all residues of febantel, fenbendazole and oxfendazole |
| | | | 10 µg/kg | Muscle, kidney, fat | |
| | | | 10 µg/kg | Milk | |
| 2.1.1.3. Oxfendazole | Combined residues of oxfendazole, oxfendazole sulfone and fenbendazole | All food producing species | 1 000 µg/kg | Liver | Provisional MRLs expire on 1. 7. 1995. The MRLs cover all residues of febantel, fenbendazole and oxfendazole |
| | | | 10 µg/kg | Muscle, kidney, fat | |
| | | | 10 µg/kg | Milk | |

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

| | | | | | |
|----------|---|----------------------------|-------------|----------------------------------|---------------------------------------|
| 2.1.1.4. | Sum of albendazole and metabolites which are measured as 2-amino-benzimidazole sulphone | Bovine | 100 µg/kg | Muscle, fat, milk, | Provisional MRLs expire on 1. 1. 1996 |
| | | Ovine | 500 µg/kg | Kidney | |
| | | | 1 000 µg/kg | Liver | |
| 2.1.1.5. | Sum of thiabendazole and 5-hydroxythiabendazole | Bovine | 100 µg/kg | Muscle, liver, kidney, fat, milk | Provisional MRLs expire on 1. 1. 1996 |
| | | Ovine | | | |
| | | Caprine | | | |
| 2.1.1.6. | Sum of triclabendazole residues that may be oxidized to ketotriclabendazole | Bovine | 150 µg/kg | Muscle, liver, kidney | Provisional MRLs expire on 1. 7. 1995 |
| | | Ovine | 50 µg/kg | Fat | |
| 2.1.1.7. | Flubendazole | Poultry | 500 µg/kg | Liver, | Provisional MRLs expire on 1. 1. 1996 |
| | | Game birds | 200 µg/kg | Muscle, | |
| | | | 400 µg/kg | Eggs | |
| Porcine | 10 µg/kg | Muscle, liver, kidney, fat | | | |
| 2.1.1.8. | Oxibendazole | Bovine | 100 µg/kg | Muscle, liver, kidney, fat | Provisional MRLs expire on 1. 1. 1996 |
| | | Ovine | | | |
| | | | 50 µg/kg | Milk | |
| | | Porcine Equidae | 100 µg/kg | Muscle, liver, kidney, fat | |

2.1.2. Tetra-hydro-imidazoles (imidazolthiazoles)

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|---------------|----------------------------|----------|----------------------------------|---------------------------------------|
| 2.1.2.1. | Levamisole | All food producing species | 10 µg/kg | Muscle, liver, kidney, fat, milk | Provisional MRL expires on 1. 1. 1995 |

2.2. Agents acting against ectoparasites

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|--|----------------|---------------|----------------|--|
| 2.2.1. Amitraz | Sum of amitraz and metabolites which are measured as 2,4-dimethylaniline | Porcine | 50 µg/kg | Muscle | Provisional MRLs expire on 1. 7. 1996. |
| | | 200 µg/kg | Kidney, liver | | |

3. Agents acting on the nervous system

3.1. Agents acting on the central nervous system

3.1.1. Butyrophenone tranquilizers

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|---------------|----------------------------|-----------|--------------------|---------------------------------------|
| 3.1.1.1. Azaperone | Azaperone | All food producing species | 100 µg/kg | Kidney | Provisional MRLs expire on 1. 1. 1996 |
| | | | 50 µg/kg | Liver, muscle, fat | |

3.2. Agents acting on the autonomic nervous system

3.2.1. Anti-adrenergics

| Pharmacologically active substance(s) | Major residue | Animal species | MRLs | Target tissues | Other provisions |
|---------------------------------------|---------------|----------------------------|----------|---------------------|---------------------------------------|
| 3.2.1.1. Carazolol | Carazolol | All food producing species | 30 µg/kg | Liver | Provisional MRLs expire on 1. 7. 1995 |
| | | | 5 µg/kg | Kidney, muscle, fat | |

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

ANNEX IV

List of pharmacologically active substances for which no maximum levels can be fixed

1. Nitrofurans, except furazolidone (see Annex III)
2. Ronidazole
3. Dapsone
4. Chloramphenicol

Status: Point in time view as at 07/11/1994.

Changes to legislation: There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94. (See end of Document for details)

- (1) OJ No L 224, 18. 8. 1990, p. 1.
- (2) OJ No L 156, 23. 6. 1994, p. 6.

Status:

Point in time view as at 07/11/1994.

Changes to legislation:

There are currently no known outstanding effects for the Commission Regulation (EC) No 2701/94.